Pfizer Inc. (PFE) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for PFE is $28.00 — 17.9% above the latest price of $23.74.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Pfizer hinges on the successful execution and commercialization of its robust R&D pipeline, particularly in high-growth areas like oncology and obesity. Positive clinical trial readouts for key candidates such as mevrometostat (prostate cancer), sigvotatug vedotin (lung cancer), and berobenatide (obesity) could significantly boost future revenues. The strong performance of recently launched and acquired products, which grew 22% operationally in Q1 2026, indicates a successful diversification strategy away from COVID-related products. Furthermore, strategic acquisitions like Seagen enhance its oncology portfolio. The reaffirmed 2026 guidance and ongoing cost efficiencies, along with a high dividend yield, provide a strong foundation for long-term value.
Bear Case
The primary risk for Pfizer is the looming 'patent cliff' between 2026 and 2028, which could lead to a significant decline in annual revenues as several blockbuster drugs lose exclusivity. The company's future growth is highly dependent on the successful development and market penetration of its pipeline, especially its obesity drugs, which carry inherent development and commercialization risks. Continued declines in COVID-19 product sales further pressure overall revenue. An unfavorable outcome in the tafamidis bench trial or other patent challenges could also negatively impact profitability. Recent executive transitions and some analyst downgrades signal potential short-term uncertainties.
Model-assessed risk level: Medium
Key Catalysts to Watch
Key data readouts and regulatory decisions for pipeline assets in oncology (e.g., mevrometostat, sigvotatug vedotin) and obesity (e.g., berobenatide) in 2026.
Continued strong performance and growth from recently launched and acquired products, offsetting COVID-19 revenue declines.
Progress and realization of approximately $7.7 billion in cost-cutting initiatives by the end of 2026.
Resolution of legal and patent challenges, such as the tafamidis bench trial.
Successful integration and synergy realization from strategic acquisitions, like Seagen.
Technical Backdrop
RSI-14
34.1
50-Day MA
$26.76
200-Day MA
$25.42
From 52-Wk High
-12.7%
Full momentum breakdown: Is PFE overbought or oversold?
Model Notes
Pfizer Inc. is a leading global biopharmaceutical company facing a transformative period. The company reported a strong first quarter in 2026, with revenues of $14.5 billion, a 5% year-over-year increase, and adjusted EPS of $0.75, exceeding analyst expectations. Growth in newly launched and acquired products, particularly in oncology and other key areas, offset significant declines in COVID-19 product revenues. Pfizer has reaffirmed its full-year 2026 financial guidance. However, the company is navigating an impending 'patent cliff' between 2026 and 2028, which is expected to impact revenues. Strategic acquisitions, a robust R&D pipeline focused on oncology and obesity, and cost-cutting initiatives are central to its long-term growth strategy. Analyst sentiment is currently mixed, with a range of 'Buy' and 'Hold' recommendations.
PFE's stock price has shown some volatility, with the current price around $24.30, near its 52-week low of $23.11, while the 52-week high is $28.75. The stock has experienced a slight daily decrease as of July 5th, 2026. Some short-term indicators suggest an uncertain outlook, with the stock testing support levels. However, its attractive dividend yield around 7% may provide some support for income-focused investors.
Current Street Context
July 6, 2026The AI price target for Pfizer (PFE) is $28.00. Analyst sentiment for Pfizer is a 'Hold' or 'Moderate Buy' consensus rating, based on a mix of buy, hold, and some sell ratings. The average 12-month price target from analysts ranges from approximately $28.73 to $30.72, with a high forecast of $36.00 or $45.00 and a low of $24.00 or $25.00. This suggests a potential upside from the current price. Upcoming key events include future earnings reports, which will be crucial for demonstrating successful execution of its pipeline, especially with growth expectations tied to obesity drugs. The outcome of the pivotal tafamidis bench trial is also noted as having a significant impact on the stock's performance. It is important to remember that price targets are estimates and not guaranteed outcomes.
Frequently Asked Questions
What is the price target for PFE?
How is this forecast generated?
How accurate are stock price predictions?
Will PFE stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews PFE’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on PFE
Pfizer Inc. Overview
Price, chart, analysis & financials
PFE: Overbought or Oversold?
Updated daily
PFE: Why Is It Moving?
Updated daily
PFE: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers